Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07171606
PHASE2
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
View on ClinicalTrials.gov
Summary
This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2025-10-24
Completion Date
2027-08-31
Last Updated
2025-12-18
Healthy Volunteers
No
Conditions
Interventions
DRUG
SSGJ-706
PD-1/PD-L1 bispecific antibody
DRUG
pemetrexed /carboplatin
chemotherapy
DRUG
Carboplatin/Paclitaxel
chemotherapy
DRUG
PD-1 Inhibitor + Chemotherapy
control group
Locations (1)
Institute of The Shanghai Pulmonary Hospital
Shanghai, China